Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q3 2025 earnings summary

Executive summary

• Achieved significant organizational restructuring, including sale of three general hospitals and contract rescissions, refocusing exclusively on oncology and divesting non-core assets.

• Raised approximately R$1.4 billion in capital, supporting deleveraging and strengthening the balance sheet, with the capital increase completed post-quarter.

• Significant non-recurring accounting charges (~R$1.8 billion) impacted reported results, requiring adjusted figures for recurring performance analysis.

• Attracted over 100 new doctors since the start of the year, reinforcing the company's appeal in the oncology sector.

• Largest private oncology provider in Brazil, operating 144 units in 47 cities, with ~670,000 treatments in LTM 3Q25 and over 2,240 oncology specialists.

Financial highlights

• Adjusted EBITDA reached R$241.4 million in 3Q25, up 30.4% sequentially, with a margin of 17.1%, up 450 basis points.

• Gross revenue in 3Q25 was R$1,579.4 million, down 9.5% YoY; net revenue was R$1,413 million, down 13.6% YoY, mainly due to discontinuation of services to Unimed FERJ.

• Cash flow from operations was R$246.4 million, driven by improved profitability and working capital efficiency.

• Organic free cash flow generation was R$62.4 million in the quarter.

• Net loss (adjusted for non-recurring items and LTIP) was R$97.9 million in 3Q25; excluding hospital operations, net loss would have been R$39.7 million.

Outlook and guidance

• Management expects the cycle of necessary adjustments to be nearing its end, with continued operational recovery and profitability expansion.

• Guidance for net revenue growth in the low double digits (10-12%) for the next periods, leveraging existing capacity and partnerships.

• CapEx expected to remain below historical levels as major investments are completed.